DGIST Signs Technology Transfer Agreement with Private Company
[Asia Economy Reporter Kim Bong-su] A domestic research team has begun clinical trials and commercialization of an Alzheimer's dementia treatment substance extracted from traditional Korean medicine. If successful, it could surpass the latest treatments currently being developed in the United States, drawing significant attention.
Daegu Gyeongbuk Institute of Science and Technology (DGIST) announced on the 12th that Professor Seo Jin-su's neuroscience team recently signed a technology transfer contract with a private company to commercialize the technology for a "composition for Alzheimer's dementia treatment based on extracts from traditional Korean medicine materials," developed jointly with the Korea Institute of Oriental Medicine. Specifically, this is a technology transfer contract worth a total of 1.2 billion KRW for the commercialization of the technology involving a composition for Alzheimer's treatment containing mixed extracts of traditional Korean medicine materials as active ingredients.
This technology developed a composition showing APOE4 genotype-specific protective effects, one of the main causes of Alzheimer's dementia. The removal effect of amyloid beta was observed in a human induced pluripotent stem cell APOE4 Alzheimer's model.
Concerns about the efficacy and safety of "Aducanumab," conditionally approved recently by the U.S. Food and Drug Administration (FDA) as an Alzheimer's treatment, have not yet been resolved. DGIST expects that if the efficacy of this technology is verified through clinical trials following the technology transfer, it will lead to the development of a more effective dementia treatment.
Professor Seo said, "It was confirmed that this technology has excellent effects on amyloid beta phagocytosis in a human Alzheimer's dementia model," adding, "I hope this technology transfer will lead to the development of a treatment."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
